Global Anti-malarial Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Aryl amino alcohol compounds, Antifolate compounds, Artemisinin compounds, and Others.

By Malaria Type;

Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malaria, and Plasmodium Ovule.

By End User;

Hospitals, Specialty Clinics, Homecare, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn147974443 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Anti-malarial Drugs Market (USD Million), 2021 - 2031

In the year 2023, the Global Anti-malarial Drugs Market was valued at USD 8,761.17 million. The size of this market is expected to increase to USD 11,078.99 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 3.4%.

With millions of cases reported annually, primarily in Africa, Southeast Asia, and South America, the need for effective anti-malarial drugs is paramount. The market for these drugs is characterized by a constant push for innovation to combat drug resistance, improve treatment efficacy, and expand access to vulnerable populations. Historically, drugs such as chloroquine and quinine were cornerstones of malaria treatment. However, the emergence of drug-resistant strains of the malaria parasite has necessitated the development of new therapeutic approaches. Artemisinin-based combination therapies (ACTs) have emerged as the frontline treatment for uncomplicated malaria, offering high efficacy and reduced risk of resistance development. The market has also seen the development of novel drugs targeting different stages of the malaria parasite's life cycle, including transmission-blocking drugs to prevent its spread.

Geographically, the market is characterized by disparities in access to treatment, with the burden of malaria disproportionately affecting low- and middle-income countries. Efforts to combat malaria include initiatives such as the Global Fund to Fight AIDS, Tuberculosis, and Malaria, which provides funding for anti-malarial interventions in endemic regions. Additionally, public-private partnerships and philanthropic endeavors play a crucial role in drug development, distribution, and community-based interventions.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Malaria Type
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Global Anti-malarial Drugs Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Drug Resistance

        2. Public Health Initiatives

        3. Research & Development

      2. Restraints
        1. Limited Access

        2. Drug Affordability

        3. Pandemic Impact

      3. Opportunities
        1. Innovative Therapies

        2. Public-Private Partnerships

        3. Expanded Distribution Networks

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Anti-malarial Drugs Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Aryl amino alcohol compounds

      2. Antifolate compounds

      3. Artemisinin compounds

      4. Others

    2. Global Anti-malarial Drugs Market, By Maleria Type, 2021 - 2031 (USD Million)
      1. Plasmodium Falciparum

      2. Plasmodium Vivax

      3. Plasmodium Malarie

      4. Plasmodium Ovale

    3. Global Anti-malarial Drugs Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Specialty Clinics
      3. Homecare
      4. Others
    4. Global Anti-malarial Drugs Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Cipla
      2. Novartis AG
      3. Strides Pharma Science Limited
      4. Glenmark Pharmaceuticals
      5. GlaxoSmithKline PLC
  7. Analyst Views
  8. Future Outlook of the Market